There are 360 resources available
125P - A phase 2a study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab (ÒPAVEÓ) in advanced non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Martina Imbimbo
Session: Poster Display
7P - PrimeCUTR: Identifying clinically relevant neoantigens in the untranslated regions of cancer genomes.
Presenter: Christopher Sng
Session: Poster Display
126P - AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab (OCI) + Tislelizumab (TIS) in Patients (pts) With Checkpoint Inhibitor (CPI)-Experienced Advanced Non-Small Cell Lung cancer (NSCLC)
Presenter: Sophia Frentzas
Session: Poster Display
8P - Phenotypic characterization of infused tumor-infiltrating lymphocytes (TIL) correlates with response to adoptive cellular therapy (ACT) in patients with metastatic melanoma (MM)
Presenter: Joachim Stoltenborg Granhøj
Session: Poster Display
127P - Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced NSCLC
Presenter: Byoung Chul Cho
Session: Poster Display
9P - Early circulating tumor DNA (ctDNA) kinetics and gene expression analysis to predict treatment outcomes with anti-PD-1 therapy
Presenter: Enrique Sanz Garcia
Session: Poster Display
128P - Neoadjuvant durvalumab plus chemotherapy in stage III non-small cell lung cancer: A phase II single-center exploratory study
Presenter: Xiaorong Dong
Session: Poster Display
10P - Deep Learning-based prediction of patientÕs TLS status from HE images in pan-cancer cohort
Presenter: Lucile Vanhersecke
Session: Poster Display
129P - Tislelizumab Combined with Bevacizumab Plus Nab-paclitaxel Single-Agent Chemotherapy for Advanced NSCLC After Resistance to EGFR TKIs
Presenter: Chengzhi Zhou
Session: Poster Display
11P - Association of VISTA expressing CD66b positive neutrophils, with response and survival benefit from pembrolizumab in advanced malignant pleural mesothelioma
Presenter: Krisztian Homicsko
Session: Poster Display